Why Is Actemra So Hard to Find? [Explained for 2026]

If you've been prescribed Actemra (tocilizumab) and arrived at the pharmacy only to be told it isn't available, you're far from alone. This powerful biologic medication — used to treat rheumatoid arthritis, giant cell arteritis, and other serious inflammatory conditions — has been one of the more difficult specialty drugs to consistently find in stock. In 2026, the supply picture has improved, but challenges remain for some patients. Here's what you need to know.

What Is Actemra and Why Is It in Such High Demand?

Actemra (tocilizumab) is a biologic medication made by Genentech that belongs to a class called interleukin-6 (IL-6) receptor antagonists. It works by blocking IL-6, a protein the immune system releases that causes inflammation. When the immune system is overactive — as it is in rheumatoid arthritis, giant cell arteritis, and other autoimmune diseases — IL-6 drives pain, swelling, and tissue damage.

Actemra has FDA approval for seven indications: moderate-to-severe rheumatoid arthritis (RA), giant cell arteritis (GCA), systemic sclerosis-associated interstitial lung disease (SSc-ILD), polyarticular juvenile idiopathic arthritis (PJIA), systemic juvenile idiopathic arthritis (SJIA), cytokine release syndrome (CRS) from CAR-T cell therapy, and hospitalized COVID-19 patients requiring oxygen support. That wide range of uses means thousands of patients depend on it — and each new indication adds to demand.

The 2021 Shortage: When COVID-19 Overwhelmed Supply

To understand why Actemra can still be difficult to find, you need to know about 2021. When the FDA granted Emergency Use Authorization for IV Actemra to treat hospitalized COVID-19 patients in June 2021, demand exploded overnight. The COVID-19 Delta variant surge that summer drove demand more than 400% above pre-pandemic levels in just two weeks, according to Genentech. By August 2021, all IV formulations were out of stock nationwide.

The crisis forced Genentech to scramble to increase manufacturing capacity. Biologic drugs like Actemra are made using living cells in a complex manufacturing process — you can't just "make more" overnight the way you might with a chemical pill. The shortage hit rheumatology and oncology patients especially hard, as their regular infusions were disrupted or delayed.

Why Biologic Drugs Are Harder to Make Than Pills

Unlike a small-molecule pill that a pharmaceutical company can synthesize in a lab, biologic drugs like Actemra are manufactured using living cell systems. The process is incredibly complex: cells must be cultured, the protein must be purified and formulated, and quality testing at every step takes months. Raw material shortages, global supply chain disruptions, and the sheer complexity of biologic manufacturing all contributed to the 2021 shortage — and continue to make the drug harder to stock consistently.

Where Does Actemra Availability Stand in 2026?

Good news: the picture in 2026 is significantly better than 2021. Genentech announced stable supply of all Actemra IV and SC configurations after dramatically increasing manufacturing capacity. More importantly, three biosimilars have now entered the market:

• Tofidence (tocilizumab-bavi) — FDA approved September 2023, IV formulation
• Tyenne (tocilizumab-aazg) — FDA approved March 2024, launched April 2024, both IV and SC
• Avtozma (tocilizumab-anoh) — FDA approved January 2025, IV launched October 2025, SC in 2026

These biosimilars have expanded the tocilizumab supply pool. However, the American College of Rheumatology has noted regional supply constraints affecting the Tyenne biosimilar in particular, due to increased demand. Some patients may still experience localized stocking gaps depending on their region and the specific formulation they need.

39,345+ patients found their medications in stock

39K+

Find Actemra In Stock Today →

Why Specialty Pharmacies Have It — But Your Corner Pharmacy Doesn't

Actemra is a specialty medication. The IV formulation is almost exclusively administered in infusion centers, hospitals, and rheumatology clinics — it isn't dispensed at retail pharmacies at all. The subcutaneous (SC) formulation (prefilled syringe or ACTPen) can be dispensed at specialty pharmacies, but most standard retail chains don't stock it. This means even in a market with "available" supply, individual patients may struggle to get the medication locally.

Payer Step Therapy: Why Your Insurance Might Steer You Away from Actemra

In 2026, many insurance plans — including major commercial insurers and Medicare — now require patients to try the biosimilar versions of Actemra (Tyenne, Avtozma) before they will cover brand-name Actemra. This "step therapy" means even patients who were previously stable on Actemra may be switched, and those starting fresh may have difficulty getting the brand approved without first trying a biosimilar. While biosimilars are therapeutically equivalent, transitions can add confusion and delays.

Skip the calls, skip the stress.

Find Actemra In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

What You Can Do If You Can't Find Actemra

If your pharmacy doesn't have Actemra in stock, here are concrete steps to take:

1. Contact your prescribing rheumatologist immediately — they may have established relationships with specialty pharmacies or infusion centers that have stock.
2. Ask about switching between IV and SC formulations — sometimes one is available when the other is not, and the ACR has supported such substitutions.
3. Discuss biosimilar options — Tyenne, Tofidence, and Avtozma are therapeutically equivalent and may be available where brand Actemra is not.
4. Use medfinder — our service calls pharmacies near you to find which ones can fill your prescription, saving you hours of phone calls.

For a deeper look at the current situation, read our Actemra shortage update for patients in 2026. If you want to understand your options when Actemra isn't available, see our guide to alternatives to Actemra when you can't fill your prescription.

The Bottom Line

Actemra is not as hard to find as it was in 2021, but it remains a specialty medication that isn't stocked at most retail pharmacies. The arrival of three biosimilars has helped, but regional gaps persist. If you're struggling to fill your prescription, don't give up — work with your prescriber, explore formulation alternatives, and use tools like medfinder to locate pharmacies near you that have it in stock.